SOHO 2026 | Insights into the clinical significance of JAK2 alterations in adult B-cell ALL
Kriti Gera, MD, Moffitt Cancer Center, Tampa, FL, discusses the clinical significance of JAK2 alterations in B-cell acute lymphoblastic leukemia (ALL). Dr Gera notes that approximately 7% of patients with B-cell ALL harbor JAK2 alterations, most with Philadelphia chromosome-like (Ph-like) ALL, and only half achieve complete remission, underscoring poor outcomes and the need to explore JAK2 inhibitor therapy in this subgroup. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I’m presenting a poster at ASH 2026 about JAK2 alterations in B-cell ALL in adult patients. So this is a subgroup which is mostly associated with the Ph-like ALL, which has poor outcomes. So I looked at a cohort of 290 patients who underwent NGS at Moffitt Cancer Center. About 7% of patients, that is about 22 patients, had JAK2 alterations. And 80% of those patients had Ph-like ALL, if we divide it through ICC category...
So I’m presenting a poster at ASH 2026 about JAK2 alterations in B-cell ALL in adult patients. So this is a subgroup which is mostly associated with the Ph-like ALL, which has poor outcomes. So I looked at a cohort of 290 patients who underwent NGS at Moffitt Cancer Center. About 7% of patients, that is about 22 patients, had JAK2 alterations. And 80% of those patients had Ph-like ALL, if we divide it through ICC category. And about 80 percent of those had point mutations. And the most common one was R683G, which is different from the V617, which we see with the myeloid diseases. One more thing I would like to point out, 60% of patients had CRLF2 alterations, which is a known category. And we do know that they are associated with the JAK2 alterations. They are a subgroup which is associated with poor outcomes. So overall, we saw that in the Ph-like ALL subgroup in this population about only half of the patients were MRD negative after, well sorry, had complete remission after induction. So the outcomes still remain poor and we should investigate further the role of JAK2 inhibitor therapy in this population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
